Clinical Trial Update: A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 trial evaluated the efficacy and safety of certolizumab pegol in Japanese patients with moderate to severe psoriasis, with results posted in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Erythrodermic Psoriasis
• Generalized Pustular Psoriasis
• To Severe Psoriasis

Drugs mentioned

• Certolizumab pegol (certolizumab pegol)

Snippet

Sponsor: UCB Biopharma S.P.R.L. | Conditions: Moderate to Severe Psoriasis, Generalized Pustular Psoriasis and Erythrodermic Psoriasis | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2019-12-11